Optibiotix Health plc

SlimBiome weight-management product, positioned as a safe, lower-cost alternative/complement to GLP-1 agonists

SlimBiome is our flagship weight loss product, clinically proven through four human studies...We have changed our focus to promoting SlimBiome as both a safe and lower cost natural alternative to GLP-1s, and increasingly as an aid to preventing weight gain when consumers stop injecting the drugs

WellBiome gut-health product with authorised on-pack health claims in Europe and USA

WellBiome is a patented, mineral-enriched multi prebiotic fibre complex... On-pack health claims authorised in Europe, and the USA

Gross margin improvement from product mix and cost discipline

The Group increased its gross profit from 38% in 2024 to 53% in 2025...gross profit which has increased by 85% to £614k (2024: £331k)

Negotiated volume discounts on core SlimBiome ingredients

the significant increase in SlimBiome orders for 2026...has enabled the Group to negotiate volume discounts on its core ingredients which is expected to reduce the cost of producing SlimBiome by 31% on H2 2026 orders, with further reductions anticipated later in the year that will potentially lead to a cost reduction of up to 48%

£1.1m charge: Share-based payments charge

We made a very strong start to the new financial year, with record orders of more than £800k from four major partners recorded in the first four weeks of 2026...With tighter cost control delivering improved margins across the Group, and an important breakthrough achieved as we move towards the commercialisation of SweetBiotix, we believe that we are on course to achieve our objective of moving all parts of the business towards profitability.

On 25 March and 27 April 2026 the Company sold 1.4m and 7.5m SBTX shares respectively, generating net proceeds of £787,000 (directors' report/note 23); a separate passage in the accounting policies note states the 27 April 2026 sale of 7.5m shares alone generated net proceeds of £673,000 — the two disclosed figures are not fully reconciled in the document as printed.

No dividends were distributed for the year to 31 December 2025 (2024: nil). The CEO report notes the Group's equity stakes in SBTX and PBX 'provide opportunities to realise value through the sale of shares or the potential of an ad hoc dividend return to shareholders.'

Auditor Gerald Edelman LLP issued an unmodified opinion that the financial statements give a true and fair view and were properly prepared under UK adopted International Accounting Standards and the Companies Act 2006; two key audit matters were identified (carrying value of intangible assets — development costs and patents; and carrying value of the parent company's investments), on both of which the auditor concluded no impairment was required. Going concern basis adopted: Directors reviewed cash and a 12-month cashflow forecast, noting 2026 revenue is tracking as anticipated and citing post-year-end share sales (net proceeds £787,000 and a further £673,000) and potential disposal of listed investments as downside mitigants; no material uncertainty was identified by the auditor.